ClinicalTrials.gg
RecruitingNCT07629583Updated Nov 5, 2026

To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

A Phase 1 interventional study of Cevostamab and Tocilizumab in Lupus Erythematosus, Systemic, sponsored by Genentech, Inc.. Recruiting at 11 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

Updated Nov 5, 2026First sites in 5 new countriesStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche — 2 open to participants now, 4 under way, 1 of them phase 3. Lupus Erythematosus, Systemic · Hoffmann-La Roche.

Planned enrollment
9th of 14
46 · median 65
Started
2026
with 2 others
Phase 1
5 of 14
1 open now
Registered
14th of 14
by date

Among the 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche, this one is the 9th largest by planned enrollment, is one of 3 that started in 2026, is one of 5 in phase 1, and was the 14th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

2 of the 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cevostamab in participants with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN).

03

Conditions studied

  • Lupus Erythematosus, Systemic
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of SLE according to the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) Classification Criteria at least 6 months prior to the first screening visit
  • Active -proven LN established within 9 months of screening, demonstrating LN per 2018 Revised International Society of Nephrology/Renal Pathology Society (ISN/RPS) criteria
  • Diagnosis of active SLE disease, as demonstrated by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score
  • Inadequate response or intolerance to, in the investigator's judgement, standard of care regimens for active SLE with or without LN

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding, or intending to become pregnant during the study or within the timeframe in which is required
  • Treatment with or non-investigational biologic therapies that directly deplete B cells (e.g., anti-CD20 or anti-CD19 monoclonal antibodies) (or blinded comparators) is prohibited within 6 months or 5 drug elimination half-lives, whichever is longer, prior to screening and during the study
  • Treatment with investigational biologic therapies that do not directly deplete B cells (or blinded comparators) is prohibited within 90 days or 5 drug elimination half-lives, whichever is longer, prior to initiation of study drug and during the study
  • Treatment of SLE/LN with non-investigational biologic therapies that do not directly deplete B cells (e.g., belimumab, anifrolumab) is prohibited within 4 weeks prior to screening and during the study
  • Treatment with CYC within 3 months prior to screening or during the study
  • History of known or suspected allergic reaction or anaphylactic reaction to cevostamab or its
  • Major surgery requiring hospitalization during the 4 weeks prior to screening or during screening, or any planned surgery or procedure requiring hospitalization during the 12 weeks following study drug administration
  • Alcohol or substance abuse within the 12 months prior to screening
  • Active infection of any kind, excluding fungal infection of the nail beds
  • History of serious recurrent or chronic infection
  • Tuberculosis (TB) infection
  • Active overlap syndrome with mixed connective tissue disease or systemic sclerosis within the 12 months prior to screening or during screening
  • Catastrophic or severe antiphospholipid syndrome within the 12 months prior to screening or during screening
  • High risk for bleeding or any condition requiring plasmapheresis, IV immunoglobulin, or acute blood product transfusions
  • Active severe or unstable lupus-associated neuropsychiatric disease, which, in the opinion of the investigator, is likely to require treatment with protocol-prohibited therapies
  • Non-SLE related CNS disease such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Dose Escalation and Expansion

    The study consists of a dose-escalation stage followed by an expansion stage. Participants in both stages will receive Cevostamab in a step-up dosing regimen, followed by a target dose.

    Drug: Cevostamab · Drug: Tocilizumab

Interventions

  • Participants will receive cevostamab IV as per the schedule given in the protocol.

    Also known as: RO7187797

  • Tocilizumab may be used as rescue medication for participants who experience a cytokine release syndrome (CRS) event.

    Also known as: Actemra/RoActemra

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Adverse Events (AEs)

    Time frame: Up to approximately 52 weeks

Secondary outcomes

  1. Serum Concentration of Cevostamab

    Time frame: Up to approximately 52 weeks

  2. Area Under the Concentration-Time Curve (AUC) of Cevostamab

    Time frame: Up to approximately 52 weeks

  3. Maximum Observed Serum Concentration (Cmax) of Cevostamab

    Time frame: Up to approximately 52 weeks

  4. Minimum Observed Serum Concentration (Cmin) of Cevostamab

    Time frame: Up to approximately 52 weeks

  5. Clearance (CL) of Cevostamab

    Time frame: Up to approximately 52 weeks

  6. Volume of Distribution at Steady State (Vdss) of Cevostamab

    Time frame: Up to approximately 52 weeks

  7. Change from Baseline in the Presence Anti-Drug Antibodies (ADAs)

    Time frame: Up to approximately 52 weeks

07

Study locations

11 of 11 sites recruiting
08

References and documents

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Mar 2030, 40 months after the start.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 40 months is above that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jun 5, 2026
StartActual
Nov 2, 2026was Oct 2026
Primary completionEst.
Mar 29, 2030
CompletionEst.
Mar 29, 2030
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added — first sites in France, Australia, Brazil, China and Italy
Show 10 added (4 Brazil, 3 China, 1 France, 1 Australia, 1 Italy)
  • Hopital Rangueil · Toulouse, France
  • Royal Melbourne Hospital · Parkville, Australia
  • Hospital Moinhos de Vento · Porto Alegre, Brazil
  • Hospital de Clnicas de Porto Alegre · Porto Alegre, Brazil
  • Hospital das Clínicas FMRP-USP · Ribeirão Preto, Brazil
  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto · Sao Jose Rio Preto, Brazil
  • Peking University First Hospital · Beijing, China
  • Peking University People's Hospital · Beijing, China
  • Pingxiang People's Hospital · Pingxiang, China
  • Istituto Clinico Humanitas · Rozzano, Italy
across 2 updates, Oct 6, 2026 – Nov 5, 2026
Start date
Oct 31, 2026→Nov 2, 2026 (actual)
Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    9 sites added — first sites in Australia, Brazil, China and Italy
    Show 9 added (4 Brazil, 3 China, 1 Australia, 1 Italy)
    • Royal Melbourne Hospital · Parkville, Australia
    • Hospital Moinhos de Vento · Porto Alegre, Brazil
    • Hospital de Clnicas de Porto Alegre · Porto Alegre, Brazil
    • Hospital das Clínicas FMRP-USP · Ribeirão Preto, Brazil
    • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto · Sao Jose Rio Preto, Brazil
    • Peking University First Hospital · Beijing, China
    • Peking University People's Hospital · Beijing, China
    • Pingxiang People's Hospital · Pingxiang, China
    • Istituto Clinico Humanitas · Rozzano, Italy
    Start date Oct 31, 2026→Nov 2, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 6, 2026
    1 site added — first site in France
    Show site
    • Hopital Rangueil · Toulouse, France
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07629583
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Jun 5, 2026
Start date
Nov 2, 2026
Primary completion
Mar 29, 2030 (estimated)
Completion
Mar 29, 2030 (estimated)
Last update
Nov 5, 2026

Study contacts

Reference Study ID Number: GA46280 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cevostamab

Start the discussion